Preclinical data, efficacy, and feasibility of studies in animals served as backbones for the clinical trials that intend to use recombinant human BMP-2 (rhBMP-2) for several bone diseases, such as: bone defects, non-union fractures, spinal fusion, root canal surgery, and osteoporosis [3]. This evidence concerns the gene BMP2 and osteoporosis.